Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow
Wednesday, June 14, 2023
Share
MGI: Pioneering Life Science Innovation Through ESHG Partnerships
Strengthening RNA Sequencing Protocols with Alithea Genomics Collaboration
MGI: Pioneering Life Science Innovation Through ESHG Partnerships Strengthening RNA Sequencing Protocols with Alithea Genomics Collaboration Glasgow, UK, 14 June 2023 – MGI Tech Co., Ltd. ("MGI"), a global leader in life science technology, unveiled significant partnerships at the ESHG Conference in Glasgow. These collaborations underscore MGI's strategic focus on the European life sciences market and its dedication to advancing innovation in sequencing and automation technologies.
MGI: A Leading Supplier of Gene Sequencing Platforms
During the Corporate Satellite meeting, MGI, renowned for its gene sequencing platforms and sample preparation systems, announced its partnership with Sistemas Genomicos. Alejandra Pérez presented impressive results of the CE-IVD Whole Exome Sequencing solution on the MGI platform. Nik Matthews, a respected scientific expert from Imperial College London, provided insights into the workflow of the new NEB library preparation solution for MGI, highlighting its benefits for DNBSEQ users. Prof. Yannis Pitsiladis presented his multi-omic approach to combating drug abuse in sports using the DNBSEQ platform, emphasizing its potential and versatility.
MGI's Commitment to Life Science Innovation
"We are excited to showcase our latest achievements at the ESHG Conference, reflecting significant advancements in life science innovation. These partnerships and collaborations exemplify MGI's commitment to driving scientific progress and transforming healthcare,” stated Dr. Yong Hou, General Manager of MGI Europe and Africa.
"By leveraging cutting-edge technologies and fostering collaborations, we aim to revolutionize genomics research, empower scientists and clinical labs with state-of-the-art solutions. This reaffirms MGI's position as a leader in the industry and highlights our dedication to pushing the boundaries of what is possible in the field of life sciences."
MGI and Alithea Genomics: A Strategic Partnership
In line with MGI's commitment to innovation in RNA sequencing, the company also signed a strategic partnership with Alithea Genomics. This Swiss company, known for challenging the status quo in bulk RNA sequencing, has developed extraction-free and massively multiplexed RNA-seq library preparation solutions with native MGI compatibility.
The event attracted a diverse audience of researchers, both in person and online, along with senior management members from MGI. The platform provided MGI with a great opportunity to strengthen its commitment to enhancing innovation through local partnerships in Europe, a market MGI considers to be a key one because of its world-class academic and public research funding, extensive regulatory landscape, and wide range of clinical applications.
For more information about MGI, please visit: MGI Tech
Note: Availability of StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents may vary by region. Products are provided for Research Use Only. Not for use in diagnostic procedures (except as specifically noted).
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
RNA SEQUENCING
MGI TECH CO., LTD.
ESHG CONFERENCE
LIFE SCIENCE INNOVATION
GENOMICS RESEARCH
Share
More news
Jun 17, 2024
MGI Tech and SeqOne Partner to Advance End-to-end Genomic Analysis
MGI has announced a collaboration with SeqOne, a leading provider of AI-driven genomic decision support software, to develop and validate comprehensive genomic analysis solutions tailored to Human Genetics and Pathology labs worldwide.
Jun 3, 2024
MGI Tech Unveils New European Headquarters in Berlin, Germany
MGI opens its new European headquarters in Berlin, featuring advanced labs, a Customer Experience Center, and showcasing the latest life science innovations and multi-omics tools.
Jun 3, 2024
MGI Shares New Data on Core DNEBSEQ Technology and Showcases Latest Sequencing Innovations at ESHG 2024
MGI Tech unveils Q40 quality data for DNBSEQ with StandardMPS 2.0 Chemistry and launches DNBelab C-TaiM 4 Single-Cell Droplet Generator at ESHG 2024, showcasing major innovations.